Sionna raises $182M for cystic fibrosis drugs different from Vertex's approach

2024-03-06

Sionna Therapeutics has raised $182 million in a Series C to test its small molecules for cystic fibrosis by targeting the mutated region of the protein at the root of the disease, unlike Vertex Pharmaceuticals, the drugmaker that pioneered medicines for the field.

The oversubscribed round was led by Enavate Sciences, part of the Patient Square Capital portfolio, the Boston-based biotech said Wednesday morning. The investor has also backed Sam Waksal’s ROCK2 biotech Graviton Bioscience and TYK2 startup Sudo Biosciences in recent months.

Sionna raises $182M for cystic fibrosis drugs different from Vertex's approach

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构